Roth 'Encouraged' by Ligand/Viking Transaction; Maintains at 'Buy' (LGND)
Tweet Send to a Friend
Roth Capital affirms Ligand Pharmaceuticals, Inc. (Nasdaq: LGND) at Buy with a target price of $92 following news that the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
